Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gargi D Basu

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Annals of Surgical Oncology|March 3, 2004
Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancerBarbara A Pockaj, Gargi D Basu, Latha B Pathangey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2008
MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinomaTeresa L Tinder, Durai B Subramani, Gargi D Basu, et al.
Anti-Cancer Drugs|March 11, 2010
The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosisMarc G Bingaman, Gargi D Basu, Tiana C Golding, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2008
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibitionPinku Mukherjee, Gargi D Basu, Teresa L Tinder, et al.
International Journal of Cancer|May 3, 2008
Functional evidence implicating S100P in prostate cancer progressionGargi D Basu, David O Azorsa, Jeffrey A Kiefer, et al.
Oncotarget|September 10, 2021
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case seriesKevin Drenner, Gargi D Basu, Laurie J Goodman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 14, 2014
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer typeZoran Gatalica, Carrie Snyder, Todd Maney, et al.
Breast Cancer Research : BCR|January 20, 2026
Characterization of ESR1 alterations in patients with breast and gynecologic cancersGargi D Basu, Paige E Innis, Angela K Deem, et al.
Journal of Translational Medicine|June 13, 2009
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancerDavid O Azorsa, Irma M Gonzales, Gargi D Basu, et al.
Oncotarget|July 25, 2025
Comprehensive genomic profiling of over 10,000 advanced solid tumorsJean-Paul De La O, Jess R Hoag, Angela K Deem, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Annals of Surgical Oncology|March 3, 2004
Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancerBarbara A Pockaj, Gargi D Basu, Latha B Pathangey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2008
MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinomaTeresa L Tinder, Durai B Subramani, Gargi D Basu, et al.
Anti-Cancer Drugs|March 11, 2010
The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosisMarc G Bingaman, Gargi D Basu, Tiana C Golding, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2008
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibitionPinku Mukherjee, Gargi D Basu, Teresa L Tinder, et al.
International Journal of Cancer|May 3, 2008
Functional evidence implicating S100P in prostate cancer progressionGargi D Basu, David O Azorsa, Jeffrey A Kiefer, et al.
Oncotarget|September 10, 2021
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case seriesKevin Drenner, Gargi D Basu, Laurie J Goodman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 14, 2014
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer typeZoran Gatalica, Carrie Snyder, Todd Maney, et al.
Breast Cancer Research : BCR|January 20, 2026
Characterization of ESR1 alterations in patients with breast and gynecologic cancersGargi D Basu, Paige E Innis, Angela K Deem, et al.
Journal of Translational Medicine|June 13, 2009
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancerDavid O Azorsa, Irma M Gonzales, Gargi D Basu, et al.
Oncotarget|July 25, 2025
Comprehensive genomic profiling of over 10,000 advanced solid tumorsJean-Paul De La O, Jess R Hoag, Angela K Deem, et al.
Pageof 3